Applicant, as named in the Orange Book
Glaxo Grp England
GSK plc · NYSE: GSK
Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings
Next listed expiry: Incruse Ellipta on 18 Dec 2027. 1 products with live protection, 0 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Incruse Ellipta NDA 205382 umeclidinium bromide | 18 Dec 2027 patent |
Recent events
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.